Brief: Alligator Bioscience Announces FDA Orphan Drug Designation For HLX22/AC101
20/03/2025 14:01
March 20 (Reuters) - Alligator Bioscience AB ATORX.ST: ALLIGATOR BIOSCIENCE ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR HLX22/AC101 IN GASTRIC CANCER UNDER TERMS OF LICENSE AGREEMENT, ALLIGATOR IS ENTITLED TO 35% OF ABCLON'S REVENUE FROM SUBLICENSE AGREEMENT WITH HENLIUS Source text: ID:nMFNmzNQm Further company coverage: ATORX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln